Norspan (Buprenorphine)

Buprenorphine binds with high affinity to the μ‑opioid receptor as a partial agonist, producing analgesia while limiting maximal respiratory depression. It also antagonizes the κ‑opioid receptor, which helps reduce dysphoric effects. The drug is absorbed through the skin, maintaining steady plasma concentrations over several days.

The appropriate patch strength and wear time are determined by the prescribing clinician based on the individual’s pain intensity, prior opioid exposure, renal and hepatic function, and overall clinical condition. Dosage adjustments are made according to therapeutic response and tolerability, not by patient self‑adjustment.

Buprenorphine is classified as Pregnancy Category C, indicating that risk cannot be ruled out. It should only be used if the potential benefit justifies the potential fetal risk. Limited data are available for breastfeeding; the drug does pass into breast milk, so clinicians should weigh benefits against possible infant exposure.

To request Norspan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Unlike full agonists such as morphine, buprenorphine is a partial μ‑opioid receptor agonist with a ceiling effect for respiratory depression, offering a potentially safer profile for long‑term use. It also has higher receptor affinity, which can reduce the need for dose escalation, but individual response varies and clinical judgment is essential.

Norspan patches should be stored at room temperature, below 25 °C, in their original sealed pouch. Protect them from direct sunlight, moisture and excessive heat. Do not fold, crush, or expose the patch to temperatures above the recommended range, as this may affect drug stability and delivery.

The patch is applied to clean, dry, hair‑free skin on the upper torso or upper arm. Press firmly for about 30 seconds to ensure good contact. Once applied, the patch remains in place for the prescribed wear period (typically 7 days) and is then removed and disposed of according to local regulations.

The most serious adverse events include respiratory depression, especially in patients with compromised pulmonary function, severe hypotension, and rare cases of allergic reactions such as anaphylaxis. Monitoring for signs of overdose, respiratory compromise, and cardiovascular instability is essential during therapy.

Norspan is contraindicated in patients with known hypersensitivity to buprenorphine or any patch components, those with severe respiratory depression, acute asthma attacks, or severe obstructive airway disease. It should also be avoided in individuals taking high‑dose full opioid agonists without careful medical supervision.